Terms: = Prostate cancer AND NUP214, ENSG00000126883, 8021, MGC104525, D9S46E, RP11-544A12_7, N214, CAIN, P35658, CAN AND Clinical Outcome
303 results:
1. Salvage Radiotherapy PSMA PET/CT-guided in Men With PSA Recurrence.
Tamburo M; Buffettino E; Pepe P; Marletta G; Pepe L; Cosentino S; Ippolito M; Pennisi M; Marletta F
Anticancer Res; 2024 May; 44(5):2205-2210. PubMed ID: 38677723
[TBL] [Abstract] [Full Text] [Related]
2. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
3. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
[TBL] [Abstract] [Full Text] [Related]
4. Early response monitoring during [
Neubauer MC; Nicolas GP; Bauman A; Fani M; Nitzsche E; Afshar-Oromieh A; Forrer F; Rentsch C; Stenner F; Templeton A; Schäfer N; Wild D; Chirindel A;
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1185-1193. PubMed ID: 38038755
[TBL] [Abstract] [Full Text] [Related]
5. Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
Siegelmann-Danieli N; Neiman V; Bareket-Samish A; Berger R; Peretz A; Alapi H; Tsur E; Patalon T; Beller D; Rimler G; Chodick G; Shohat M
Prostate; 2024 Jan; 84(1):39-46. PubMed ID: 37842866
[TBL] [Abstract] [Full Text] [Related]
6. Early biochemical and radiographic response after one cycle of [
Cytawa W; Hendel R; Tomasik B; Weinzierl FX; Bley T; Jassem J; Schirbel A; Buck AK; Bundschuh RA; Hartrampf PE; Werner RA; Lapa C
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3765-3776. PubMed ID: 37474735
[TBL] [Abstract] [Full Text] [Related]
7. PSMA-heterogeneity in metastatic castration-resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy.
Derlin T; Riethdorf S; Schumacher U; Lafos M; Peine S; Coith C; Ross TL; Pantel K; Bengel FM
Prostate; 2023 Aug; 83(11):1076-1088. PubMed ID: 37147881
[TBL] [Abstract] [Full Text] [Related]
8. Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant prostate cancer.
Omlin A; Cathomas R; von Amsberg G; Reuter C; Feyerabend S; Loidl W; Boegemann M; Lorch A; Heidenreich A; Tsaur I; Larcher-Senn J; Buck SAJ; Mathijssen RHJ; Jaehde U; Gillessen S; Joerger M
Clin Cancer Res; 2023 May; 29(10):1887-1893. PubMed ID: 36917691
[TBL] [Abstract] [Full Text] [Related]
9. Synthesis and evaluation of 7-(3-aminopropyloxy)-substituted flavone analogue as a topoisomerase IIα catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells.
Jeon KH; Park S; Shin JH; Jung AR; Hwang SY; Seo SH; Jo H; Na Y; Kwon Y
Eur J Med Chem; 2023 Jan; 246():114999. PubMed ID: 36493620
[TBL] [Abstract] [Full Text] [Related]
10. Accumulation of copy number alterations and clinical progression across advanced prostate cancer.
Grist E; Friedrich S; Brawley C; Mendes L; Parry M; Ali A; Haran A; Hoyle A; Gilson C; Lall S; Zakka L; Bautista C; Landless A; Nowakowska K; Wingate A; Wetterskog D; Hasan AMM; Akato NB; Richmond M; Ishaq S; Matthews N; Hamid AA; Sweeney CJ; Sydes MR; Berney DM; Lise S; ; Parmar MKB; Clarke NW; James ND; Cremaschi P; Brown LC; Attard G
Genome Med; 2022 Sep; 14(1):102. PubMed ID: 36059000
[TBL] [Abstract] [Full Text] [Related]
11. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
[TBL] [Abstract] [Full Text] [Related]
12. Grade migration and important prognostic factors in a pathology specimen for radical radiotherapy in prostate cancer patients.
Majewski W; Lange D; Stanek-Widera A; Itrych B; Krzysztofiak T; Jarząb M; Oczko-Wojciechowska M; Kajor M; Tarnawski R
Pol J Pathol; 2022; 73(1):27-33. PubMed ID: 35848478
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients.
Schlack K; Seitzer K; Wüstmann N; Humberg V; Grundmann N; Steinestel J; Tiedje D; Rahbar K; Krabbe LM; Bögemann M; Schrader AJ; Bernemann C
Sci Rep; 2022 Jul; 12(1):11846. PubMed ID: 35831403
[TBL] [Abstract] [Full Text] [Related]
14. Malignancy Diseases in Kidney Transplantation, clinical outcomes, Patient, and Allograft Survival: A Case-Control Study.
Pinto-Filho VA; Nascimento E; Cunha APL; Assis BPS; Lasmar MF; Vianna HR; Fabreti-Oliveira RA
Transplant Proc; 2022 Jun; 54(5):1253-1261. PubMed ID: 35750515
[TBL] [Abstract] [Full Text] [Related]
15. Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of clinical Response in Castration-Sensitive prostate cancer.
Sowalsky AG; Figueiredo I; Lis RT; Coleman I; Gurel B; Bogdan D; Yuan W; Russo JW; Bright JR; Whitlock NC; Trostel SY; Ku AT; Patel RA; True LD; Welti J; Jimenez-Vacas JM; Rodrigues DN; Riisnaes R; Neeb A; Sprenger CT; Swain A; Wilkinson S; Karzai F; Dahut WL; Balk SP; Corey E; Nelson PS; Haffner MC; Plymate SR; de Bono JS; Sharp A
Clin Cancer Res; 2022 Aug; 28(16):3509-3525. PubMed ID: 35695870
[TBL] [Abstract] [Full Text] [Related]
16. High eEF1A1 Protein Levels Mark Aggressive prostate cancers and the In Vitro Targeting of eEF1A1 Reveals the eEF1A1-actin Complex as a New Potential Target for Therapy.
Bosutti A; Dapas B; Grassi G; Bussani R; Zanconati F; Giudici F; Bottin C; Pavan N; Trombetta C; Scaggiante B
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456960
[TBL] [Abstract] [Full Text] [Related]
17. Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies.
Rijstenberg LL; Hansum T; Kweldam CF; Kümmerlin IP; Remmers S; Roobol MJ; van Leenders GJLH
Histopathology; 2022 Jun; 80(7):1041-1049. PubMed ID: 35384019
[TBL] [Abstract] [Full Text] [Related]
18. clinical outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant prostate cancer After Failure of First-line Androgen Receptor Axis-targeted Therapy.
Fujiwara M; Fujiwara R; Oguchi T; Komai Y; Numao N; Yamamoto S; Yonese J; Yuasa T
Anticancer Res; 2022 Apr; 42(4):2123-2130. PubMed ID: 35347036
[TBL] [Abstract] [Full Text] [Related]
19. A pipeline for copy number profiling of single circulating tumour cells to assess intrapatient tumour heterogeneity.
Deger T; Mendelaar PAJ; Kraan J; Prager-van der Smissen WJC; van der Vlugt-Daane M; Bindels EMJ; Sieuwerts AM; Sleijfer S; Wilting SM; Hollestelle A; Martens JWM
Mol Oncol; 2022 Aug; 16(16):2981-3000. PubMed ID: 34964258
[TBL] [Abstract] [Full Text] [Related]
20. clinical outcome of Salvage Radiotherapy for Locoregional clinical Recurrence After Radical prostatectomy.
Lee SU; Cho KH; Kim JH; Kim YS; Nam TK; Kim JS; Cho J; Choi SH; Shim SJ; Kim JH; Chang AR
Technol Cancer Res Treat; 2021; 20():15330338211041212. PubMed ID: 34806469
[No Abstract] [Full Text] [Related]
[Next]
